Dr. Brian L. Clevinger is a founder and managing director of Prolog. He has actively participated in all phases of commercial technology development for more than 15 years. Prior to joining Prolog, Dr. Clevinger was the CEO of Megan Health which developed vaccines. He held this position from Megan's inception until its acquisition by AVANT Immunotherapeutics (AVAN). Previously, he was the president of A/W Company. Working with Washington University researchers, he evaluated numerous technologies, selected the most commercially promising ones for funding, and served on the board of each resulting enterprise. Before joining A/W Company, he held a tenured position and ran a research laboratory at Washington University. He holds a doctorate degree from Indiana University in immunology and completed his postdoctoral fellowship at Washington University.